Business insights and articles written by our team of world-class professionals
With a strong track record across APAC, Francis Wan’s appointment marks a powerful acceleration of Medison’s growth in the region ZUG, Switzerland— [October 23rd, 2025]
1 October 2025. Medison Pharma Australia Pty Ltd (“Medison”), alongside their partner Alnylam Pharmaceuticals, Inc. (“Alnylam”), is pleased to announce that from October 1st 2025,
BylvayTM is the first and only medication approved in Canada for the treatment of both Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis TORONTO,
Strategic appointments reflect Medison’s continued investment in global scale and operational excellence PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ — Medison, the creator of a first-of-its-kind unified global commercialization
1 May 2025. Medison Pharma Australia Pty Ltd (“Medison Pharma”), alongside their partner Alnylam Pharmaceuticals, Inc. (“Alnylam”), is pleased to announce that from 1 May
KIMMTRAK (tebentafuspe) is the first and only approved treatment for Brazilian adult patients living with this disease SÃO PAULO, Brazil – [March 18th, 2025]:
Sydney, Thursday 1 August, 2024. Medison Pharma, alongside their partner Alnylam Pharmaceuticals, Inc., are pleased to announce that from 1 August 2024, ONPATTRO® (patisiran) is
The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance Medison, the creator and leader
Sydney, Thursday 1 February, 2024. Medison Pharma, alongside their partner Immunocore Holdings Ltd (NASDAQ: IMCR), is pleased to announce that from today KIMMTRAK® (tebentafusp)